Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Core Insights - Dyne Therapeutics, Inc. is a clinical-stage company focused on developing innovative therapeutics for genetically driven neuromuscular diseases [3] Group 1: Company Overview - Dyne Therapeutics is dedicated to discovering and advancing life-transforming therapeutics for individuals with genetically driven neuromuscular diseases [3] - The company utilizes its FORCE™ platform to create targeted therapeutics aimed at improving delivery to muscle tissue and the central nervous system (CNS) [3] - Dyne has a diverse pipeline addressing various neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease [3] Group 2: Upcoming Events - Management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. ET [1] - A live webcast of the presentation will be available on Dyne's website, with a replay accessible for 90 days following the event [2]